midi health compounded semaglutide Review: GLP-1 Provider & Genetic Testing – PlexusDx What to Know About Midi's
Description
Overall, 35% heard about compounded GLP-1 concerns
[51]
The temporal association proved particularly concerning, with increased NAION risk appearing highest within the first year of semaglutide treatment
Longenecker JZ, Petrosino JM, Martens CR, Hinger SA, Royer CJ, Dorn LE, Branch DA, Serrano J, Stanford KI, Kyriazis GA, Baskin KK, Accornero F
10 Multisociety guidelines were subsequently published that emphasized the need for high-quality data
Long-term weight loss maintenance data beyond 68 weeks for Retatrutide are still limited
